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S U M M A R Y
Background: Determining which babies should receive antibiotics for potential early onset sepsis (EOS) is
challenging. We performed a meta-analysis quantifying how many EOS cases might be ‘missed’ using the
Kaiser Permanente electronic calculator, compared with National Institute for Health and Care Excellence
(NICE) guidelines.
Methods: A systematic literature search was carried out for studies citing the article in which the calculator
was publicised. Studies were eligible if they presented data evaluating the calculator, either by retrospective
case review or prospective cohort study. The primary outcome measure was numbers of culture positive EOS
cases where the calculator did not recommend empirical antibiotics, but NICE guidelines would have. Data
were pooled using a random effect meta-analysis. A subgroup analysis was performed using data from stud-
ies of babies exposed to chorioamnionitis.
Findings: Eleven studies were included. There were a total of 75 EOS cases across the studies and a minimum
of 14 (best case scenario), and a maximum of 22 (worst case scenario) cases where use of the calculator
would have resulted in delayed or missed treatment, compared to if NICE guidelines had been followed. The
probability of missed/delayed treatment for an EOS case were best case 0.19 [95% conﬁdence intervals 0.11 
0.29], worst case 0.31 [95% CI 0.17  0.49]. The probability of missing cases was signiﬁcantly more in babies
exposed to chorioamnionitis
Interpretation: A large proportion of EOS cases were ‘missed’ by the calculator. Further evaluation of the cal-
culator is recommended before it is introduced into UK clinical practice.
Funding: None.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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1. Introduction
Early onset neonatal sepsis (EOS) is deﬁned as infection occurring
within 72 h of birth. Babies with EOS may be asymptomatic initially,
whilst non-infective pathology can mimic EOS; determining who
should receive antibiotics is challenging. In the UK, babies are treated
based on risk factors and clinical indicators (see Tables 1 and 2) as
deﬁned by the National Institute for Health and Care Excellence
(NICE) [1].
Neonatal antibiotic administration has been reported to be associ-
ated with pain, parental anxiety and separation, and in childhood:
asthma, allergy and autoimmune disease [2], as well as presenting
signiﬁcant workload and ﬁnancial cost.
An electronic risk calculator has been developed by Kaiser Perma-
nente (KP), for babies born  34 weeks gestation, to aid decision
making when considering EOS. It is available online: https://neonatal
sepsiscalculator.kaiserpermanente.org/InfectionProbabilityCalcula
tor.aspx.
In a high-proﬁle paper published in JAMA Pediatrics it was shown
to reduce empirical antibiotic use substantially [3]. The calculator
contains the following ﬁelds: background EOS incidence, gestational
age, highest maternal antepartum temperature, rupture of mem-
branes in hours, maternal GBS status and type/timing of intrapartum
antibiotics. Clinical presentation is factored in, which adjusts the ‘at
birth’ recommendation given by the calculator. Empirical antibiotics
are recommended when the risk is  3/1000 births, or a blood culture
and observation if the risk is  1/1000 live births.
The use of a calculator as part of a strategy of managing neonatal
EOS adds an objective element to the decision to give or withhold
antibiotics. It is vital that the calculator is thoroughly evaluated; it
provides an exciting opportunity to provide tailored treatment, but
because EOS is rare, it could take substantial time before any* Corresponding author.
E-mail address: katherine.pettinger@nhs.net (K.J. Pettinger).
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additional ‘missed’ cases of EOS became apparent. In addition, we
should be cautious when extrapolating results between countries,
because of differences in the EOS incidence and in healthcare practi-
ces (e.g. national screening programmes for GBS). Given the impres-
sive reduction in antibiotic usage which has been demonstrated [3],
we wanted to investigate whether this might be at the expense of
delaying or missing treatment for some babies with true sepsis.
The aim of this meta-analysis was to pool all the data for available
studies of the calculator, to determine the proportion of babies with
culture proven EOS which would have been treated using NICE
guidelines but were not identiﬁed as requiring empiric antibiotics by
the calculator.
2. Methods
2.1. Search strategy and selection criteria
We carried out a systematic review and meta-analysis of the sen-
sitivity of the KP EOS calculator, in studies where it was either imple-
mented or compared theoretically to standard practice.
2.1.1. Eligibility criteria
Any studies using the calculator in babies which reported the
number of cases of EOS in the study period were eligible for inclusion.
No studies prior to 2011 (when the calculator was ﬁrst described [4])
were included. Papers where there were no cases of EOS in the study
period were excluded, as uninformative to the sensitivity calculation.
Individual patient level data was sought. Review articles and com-
mentaries, where no new data were presented, were excluded. Only
one report of each cohort was included. No language limits were
applied.
2.1.2. Outcome measures
The proportion of cases of EOS which would have been ‘missed’,
or where treatment would have been delayed by using the calculator,
were compared to NICE guidelines. We considered any baby with
positive blood cultures and an EOS risk score of <3/1000 as being a
‘miss’ only if the NICE guidelines would have recommended treat-
ment (as per Tables 1 and 2). Any cases where treatment was not rec-
ommended by the calculator, but this was concordant with NICE
guidelines, were not classiﬁed as a ‘miss’.
2.1.3. Search
The search was carried out by two authors independently (KJP/
KM), using a modiﬁed cluster technique, snowballing from studies
citing the 2017 JAMA pediatrics paper [3]. Citing articles were sought
on Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other
Non-Indexed Citations, Daily and Versions(R) 1946 to July 23, 2019,
Embase 1996 to 2019 Week 29 and Maternity & Infant Care Database
(MIDIRS) 1971 to May 2019, and Google scholar with the “Since
2017” ﬁlter on 24/07/2019. Reference lists of included articles were
reviewed, and relevant articles included. To ensure a complete data-
set, we searched for any papers that might have been published by
Table 1
Risk factors for EOS deﬁned by NICE (1).
 Invasive group B streptococcal (GBS) infection in a previous baby
 Maternal GBS colonisation, bacteriuria or infection in current pregnancy
 Prelabour rupture of membranes
 Preterm birth following spontaneous labour
 Rupture of membranes for > 18 h in a preterm birth
 Intrapartum fever > 38 °C, or conﬁrmed or suspected chorioamnionitis
 Parenteral antibiotic treatment given to the woman (red ﬂag)
 Suspected or conﬁrmed infection in another baby in the case of a multiple
pregnancy (red ﬂag)
Research in context
Evidence before this study
Early onset sepsis (EOS) is a rare but signiﬁcant cause of mortal-
ity and morbidity in neonates. Current guidelines lead to large
numbers of well babies receiving antibiotics. The Kaiser-Perma-
nente calculator has been shown to reduce antibiotic usage in
several international settings.
We carried out a systematic review using a modiﬁed cluster
technique, snowballing from studies citing the 2017 JAMA
pediatrics paper describing the calculator and its implementa-
tion. Citing articles were sought on Ovid MEDLINE(R) and Epub
Ahead of Print, In-Process & Other Non-Indexed Citations, Daily
and Versions(R) 1946 to July 23, 2019, Embase 1996 to 2019
Week 29 and Maternity & Infant Care Database (MIDIRS) 1971
to May 2019, and Google Scholar with the “Since 2017” ﬁlter on
24/07/2019. Risk of bias was assessed using QUADAS-2 and was
low/moderate for all included articles.
Added value of this study
The probability of missed or delayed treatment for an EOS case
(in addition to cases missed by NICE guidelines) were at best
0.19 [95% conﬁdence intervals 0.110.29, I2 0%], worst case
0.31 [95% conﬁdence intervals 0.170.49, I2 37%]. Amongst a
subset of babies exposed to chorioamnionitis, the calculator
appears more likely to miss cases. The number of cases of EOS
on which the calculator has been tested has not reached the
threshold for effective external validation.
Implications of all the available evidence
Whilst antibiotic use was reduced in all included studies, a large
proportion of EOS cases are ‘missed’ by the calculator, additional
to cases which would be missed by current guidelines.
Table 2
Clinical indicators of possible EOS described by NICE (1).
 Altered behaviour or responsiveness
 Altered muscle tone (e.g. ﬂoppiness)
 Feeding difﬁculties / intolerance
 Abnormal heart rate
 Signs of respiratory distress
 Respiratory distress starting > 4 h after birth (red ﬂag)
 Hypoxia
 Jaundice within 24 hrs after birth
 Apnoea
 Encephalopathy
 Seizures (red ﬂag)
 Need for CPR
 Mechanical ventilation in a term baby (red ﬂag)
 Persistent pulmonary hypertension
 Temperature abnormality
 Signs of shock (red ﬂag)
 Bleeding, thrombocytopenia, or abnormal coagulation
 Oliguria
 Altered glucose homeostasis
 Metabolic acidosis
 Local signs of infection
2 K.J. Pettinger et al. / EClinicalMedicine 19 (2020) 100227
the developers of the tool without citing Kuzniewicz et al.’s 2017
JAMA pediatrics paper. The calculator’s origins are described by Puo-
polo et al. in a 2011 paper [4]. We searched Medline, MEDIRS and
Embase for each author’s publications since 2011 for any additional
papers. Posters presented at conferences were included where possi-
ble. Clinicians known to be using the calculator were contacted and
asked to share data.
2.1.4. Study selection
Once duplicates were removed, the abstracts of all the articles
from the search were reviewed independently by two authors (KP
and KM), discussing any differences. A third was available for resolu-
tion, if required.
2.1.5. Data analysis
The number of EOS cases in each study period and the number of
those which were ‘missed’ or where treatment was delayed when
compared to NICE guidelines (as per Tables 1 and 2) was recorded,
using the study authors’ calculation of risk based on their local base-
line rate of infection (note that this varied between studies). Where
there was uncertainty about whether a case would be ‘missed’ or not,
the authors were contacted for further details and clariﬁcation. A sen-
sitivity analysis was undertaken.
2.1.6. Data items
Where possible, we collected the following data from included
studies:
 Number of babies in the sample
 Location
 Date of data collection
 Organism grown
 Clinical condition at birth (well, equivocal or ill by KP stand-
ards)
 Gestational age
 Highest maternal temperature
 Maternal GBS status
 Duration of membrane rupture
 Maternal antibiotics
 EOS risk at birth and after examinationRisk of bias across studies
The risk of bias across studies (“publication bias”) was not statisti-
cally assessed.
2.1.7. Risk of bias in individual studies
The risk of bias was assessed for each included study using QUA-
DAS-2 risk of bias assessment tool, see Table 3 and Supplementary
table S2.
2.1.8. Subgroup analyses
There has been discussion in the literature about the use of the
calculator amongst higher-risk groups of babies, speciﬁcally, babies
exposed to chorioamnionitis [5,6]. We therefore performed a sub-
group analysis of all papers focussed on chorioamnionitis exposed
babies.
2.1.9. Sensitivity analyses
Determining which cases were missed by the calculator compared
to NICE guidelines, presented some challenges. Maternal fever may
prompt a clinical team to commence parenteral antibiotics for possi-
ble maternal sepsis/chorioamnionitis. Parenteral antibiotics given up
to 24 h after birth are a red ﬂag for neonatal sepsis, but maternal
fever in isolation is not an indicator for neonatal antibiotics [1]. If
papers did not specify whether a mother was being treated for possi-
ble sepsis or chorioamnionitis, it was not possible to say whether the
baby would have been treated according to NICE guidelines. Dr Kuz-
niewicz advised that when in doubt, they would classify a high
maternal temperature as potential sepsis, in order to give a conserva-
tive evaluation of the calculator.
For completion, we performed two meta-analyses, a ‘worst case’
scenario where uncertain cases were recorded as a ‘miss’, and a ‘best
case’ scenario where the uncertain cases were treated as if they were
not missed.
2.1.10. Summary measures
The principle summary measure is the proportion of delayed/
missed treatment of EOS using the calculator compared to NICE
guidelines.
2.1.11. Synthesis of results
The pooled proportion of delayed/missed cases was estimated by
a binomial-normal model (rma.glmm) of logit transformed propor-
tions in the metafor package of R. The effect of being in a whole-pop-
ulation cohort vs. a high-infection risk cohort was evaluated as a
moderator variable. Heterogeneity between studies was assessed
describing I2.
3. Results
3.1. Study selection
The initial literature search produced 144 papers, see Fig. 1. Dupli-
cates were removed leaving 90 articles. The Kuzniewicz 2017 article,
two articles found on reviewing reference lists and a conference
poster were added resulting in 94 papers which were reviewed in
detail. No relevant additional papers were found by searching for
publications from the authors of Puopolo 2011 [4]. 15 studies were
reviewed in depth. One study was excluded because there were no
cases of EOS [7]; a further was excluded as no information on the
number of EOS cases was provided [8]. One study was excluded as it
was not possible to extract individual patient level data [9]. A further
study was excluded as it was not possible to determine whether the
participants were started on antibiotics due to strict adherence to
guidelines [10]. 11 studies met the inclusion criteria.
3.2. Study characteristics
The studies are summarised in Table 3. The largest is Kuzniewicz
2017 [3], where the calculator was introduced into practice in place
of national guidance. Dhudasia 2018 [11], Strunk 2018 [12] and Arora
2019 [13] are cohort studies where the calculator was formally intro-
duced as standard clinical practice and antibiotic use before and after
introduction compared. Sharma 2019 [14] is similar; the calculator
was introduced prospectively into clinical practice, but the paper
relates speciﬁcally to babies exposed to chorioamnionitis. Due to
insufﬁcient data availability, we had to exclude the pre-intervention
group in Arora 2019 [13] because we were unable to determine
which cases would have been missed.
Carola 2018 [15], Shakib 2015 [16] and Money 2017 [17] were
comparing retrospectively and theoretically how many babies would
have been recommended treatment in a subset of babies born to
mothers with conﬁrmed or suspected chorioamnionitis.
Joshi 2019 was a quality improvement project mainly relating to
serial physical examinations as an alternative method to manage
babies exposed to chorioamnionitis [18]. It was eligible for inclusion
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Table 3
Summary of included articles.
Location Study type Dates Population EOS data Antibiotic usage Risk of bias as per
QUADAS-2
Kuzniewicz
et al. (2017)
California, USA Prospective
single-centre cohort
2010  2015 Baseline period: 95,543
babies
Calculator period:
56,261 babies
35 weeks gestation
Epoch 1: 24 cases of EOS
4 missed by calculator.
Epoch 2: 15 cases of EOS
2 missed by the calculator, plus 4 additional possible
mises
Epoch 3: 12 cases of EOS
2 missed by calculator as conﬁrmed following d/w
Dr Kuzniewicz
Antibiotic use reduced
from 5.0% to 2.6%
low
Dhudasia
et al. (2018)
Philadelphia, USA ‘retrospective’
single-centre cohort
Epoch 1:
March 2014-May 2015
Epoch 2:
July 2015 - October 2016
Epoch 1: 5692 babies
Epoch 2: 6090 babies
36 weeks gestation
4 cases of EOS: 1 £ GBS, 3 £ E. coli
maximum 3 misses, minimum 1 miss
Case 1 E. coli - maternal temp 38.8C, on parenteral
antibiotics, initial risk score: 1.54, after examination:
7.66 - could have been a delay in treatment, depending
on how old baby was when symptoms developed
F = possible miss
Case 2 GBS  score at birth 0.3. Tachypnoeic at 36hours
which is a NICE red ﬂag for antibiotics, therefore 
miss.
Case 4 E. coli - unclear if mother was treated for
chorioamnionitis maternal temp 39C. Score at birth:
3.41 but was ‘well’; score after examination: 1.40 =
possible miss
note the authors used different thresholds: we used the
thresholds in Kuzniewicz 2017 for consistency
Antibiotic use reduced
from 6.3% to 3.7%
low
Strunk
et al. (2018)
Subiaco, Western
Australia
Prospective, single-
centre cohort
Epoch1:
Oct 2014 - January 2015
Epoch 2:
July -December 2016
Epoch1: 1731 babies
Epoch 2: 2502 babies
35 weeks gestation
2 cases of EOS
1 case in each epoch, both were clinically unwell
requiring admission to the neonatal unit.
The calculator recommended empirical treatment in both
cases, therefore, no missed cases
Antibiotic use reduced
from 12.0% to 7.6%
low
Goel et al.
(2019)
Wales, UK Prospective cohort
(EOS calculator results
not acted upon  NICE
guidelines followed)
FebruaryApril 2018 3593 babies
34 weeks gestation
7 positive blood cultures, 2 contaminants (Staph. aureus
and alpha-haemolytic streptococci)
5 cases of EOS
3 £ cases picked up by both NICE and calculator
2 £missed by both, therefore no misses compared to
NICE
Antibiotic use would
have been reduced
from 16% to 4.3%,
74% relative reduction
low
Arora et al.
(2019)
Illinois, USA Prospective, single-
centre cohort
August 2016
September 2017
276 babies
34 weeks gestation
admitted to neonatal
unit
1 case of EOS
Treated with empirical antibiotics according to calculator
recommendations, therefore no misses
Antibiotic use
reduced from
70.3% to 49.6%
low
Stipelman
et al. (2019)
Utah, USA Single centre, prospec-
tive quality improve-
ment programme
June 2014  December
2017
11,924 babies admitted
to a newborn nursery
unclear gestation
187 infants were
excluded because
their treatment was
decided by NICU clini-
cians who had not
received the quality
improvement
training.
3 cases of EOS, 1 £ GBS, 1 £ Enterococcus faecalis, 1 £ E.
coli
2 misses:
Case 1: GBS
score at birth: 0.09; well: 0.04, equivocal: 0.43, ill: 1.83
Treated because became clinically ill at 6 h. This is a
miss it ﬁts NICE criteria for treatment based on
clinical indicators but scored <3.
Case 2: Enterococcus faecalis
score at birth: 0.25;
Maternal chorioamnionitis and prolonged rupture of
membranes. Would most likely have been treated from
birth using NICE guidelines.
Antibiotic use
reduced from
7% to 1%
low
(continued on next page)
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Table 3 (Continued)
Location Study type Dates Population EOS data Antibiotic usage Risk of bias as per
QUADAS-2
Shakib
et al. (2015)
Utah, USA Single centre, retrospec-
tive record review
2006 2013 698 babies
34 weeks gestation
born to mothers with
chorioamnionitis
6 positive blood cultures, 5 contaminants (4x CoNS, 1 £
micrococcus)
1 case of EOS: GBS
No misses - EOS risk score for the GBS case was 7.85 per
1000
Antibiotic use would
have been reduced to
12%
Low-moderate
Money
et al. (2017)
Staten Island,
NY, USA
Single centre, retrospec-
tive record review
2009  2016 362
babies
“term” babies, unwell
babies excluded
born to mothers with
chorioamnionitis
3 positive blood cultures, 2 contaminants (1 £ CoNS, 1 £
Actinomyces odontolyticus)
1 case of EOS: Enterococcus
Enterococcus: highest maternal temp 38.1 °C, 20 h ROM,
chorioamnionitis exposed.
EOS risk score was 0.77/1000 = 1 £miss
Antibiotic use would
have been reduced
from 99.7% to 2.5%
Low-moderate
Carola
et al. (2018)
Philadelphia,
USA
Single centre, retrospec-
tive record review
2006  2017 896 babies
35 weeks gestation
born to mothers with
chorioamnionitis
5 cases of EOS
1 £ GBS, 1 £ E. coli, 3 £ ‘other’ Streptococci
minimum 1 miss, maximum 3.
E. coli: at birth score: 2.39, after examination: 0.98,
therefore miss
GBS: at birth score: 4.02, after examination: 1.65, possible
miss, depending which score was used
Strep. sanguinis: at birth score 2.03, after examination
41.34, possible miss, depending which score was used
Antibiotic use would
have been reduced to
23.5%
Low-moderate
Sharma et al.
(2019)
Minneapolis,
USA
Single-centre prospec-
tive cohort study
Pre implementation Jan-
uary - December 2015
post implementation:
April 2016 - March
2018
epoch 1: 109 babies
epoch 2: 180 babies
36 weeks gestation
born to mothers with
chorioamnionitis
1 case of EOS
Treated with empirical antibiotics according to calculator
recommendations, therefore no misses
Antibiotic use reduced
from 40% to 23%
low
Joshi et al.
(2019)
Stanford, USA Single centre, retrospec-
tive record/chart
review, as part of a
separate quality
improvement project
20152017 339 babies
34 weeks’ gestation
born to mothers with
chorioamnionitis
1 case of EOS: GBS
Highest maternal temp 38.3 °C, known maternal GBS
carriage but untreated, chorioamnionitis exposed. EOS
score at birth was 0.93 per 1000, therefore= 1 £miss
Antibiotic use reduced
by 12.3% to 5.1%, but
this was not achieved
by using the calculator
Low-moderate
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because the authors had compared their results to those which might
have been achieved using the calculator and presented data on the
number of EOS cases.
Goel 2019 was a prospective cohort study comparing the calcula-
tor against NICE guidelines. All babies were managed according to
NICE guidelines, and the calculator recommendations were not acted
upon [19].
Stipelman 2019 was a 2 phased quality improvement project,
designed to improve uptake of the calculator in their centre [20].
There was sufﬁcient data to incorporate it into the meta-analysis.
3.3. Results of individual studies
See and Supplementary Table S1  data extracted from articles,
excluding contaminants.
3.4. Risk of bias across studies
When blood culture results are known, i.e. in retrospective stud-
ies, it is possible that the clinical condition of the baby at birth may
be recorded differently in the light of this, introducing bias. This is a
potential issue for Joshi 2019, Shakib 2015, Money 2017 and Carola
2018 which evaluated the calculator retrospectively (using contem-
poraneous notes). Kuzniewicz 2017, Dhudasia 2018, Strunk 2018,
Sharma 2019 and Arora 2019 had retrospective comparison groups
which could also have been affected.
Kuzniewicz 2017, Dhudasia 2018, Strunk 2018, Sharma 2019,
and Arora 2019 were using the calculator prospectively and were
at risk of a different form of bias, that is, their retrospective inter-
pretation of the national guidelines. For example, a baby born to a
febrile mother, who has a low EOS score, but goes on to become
septic. According to the calculator the baby would not receive
Fig. 1. Study selection.
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immediate antibiotics. However, a clinician using national guide-
lines could have been more conservative and treated the baby
empirically in case of possible maternal sepsis. The interpretation
of such ﬁndings is not clearly described and may be a source of
potential bias.
Dhudasia 2018 is the only paper which explains exactly how the
“at birth” and “after examination” scores were acted upon; nursing
staff calculated the risk at birth for every baby, and if it was > 0.7/
1000 then the paediatrician was alerted, and the baby examined.
No clear evidence of publication bias was noted.
3.5. Synthesis of results
Across the studies there were 75 cases of culture proven EOS.
There was a minimum of 14 (best case scenario), and a maximum of
22 (worst case scenario), cases of EOS where the calculator did not
recommend empirical antibiotics, i.e. they would have been/were ini-
tially ‘missed’ compared to NICE guidelines, see supplementary table
S3.
The pooled probability of missing a case of EOS, which would not
have been missed by the NICE guidelines, were best case 0.19 [95%
conﬁdence interval (CI) 0.110.29, I2 0%] (see Fig. 2), worst case 0.31
[95% CI 0.170.49, I2 37%] (see Fig. 3). Exclusion of the papers focused
on chorioamnionitis exposed babies [1418] did not alter these esti-
mates meaningfully (0.17 vs 0.19, and 0.26 vs 0.31 for the ‘best’ and
‘worst’ case analyses, see Figs. 4 and 5). Studies which retrospectively
evaluated the calculator in babies exposed to chorioamnionitis
showed the calculator performed less well: best case scenario 0.33
[95% CI 0.11  0.67, I2 0%] (see Fig. 6), worst case scenario 0.56 [95%
CI 0.25  0.82, I2 0%] (see Fig. 7) (test for subgroup difference,
p = 0.03).
4. Discussion
This systematic review and meta-analysis has demonstrated that,
compared to the NICE guidelines the probability of the calculator
missing a case of EOS were best case 0.19 [0.11  0.29], worst case:
0.31 [0.17  0.49]. Amongst a subset of babies exposed to chorioam-
nionitis, the calculator appears more likely to miss cases; the proba-
bility of missing cases was best case 0.33 [0.11  0.67], worst case
0.56 [0.25  0.82]. The studies were relatively homogeneous; the
patient groups were similar (all neonates <72hours old, all >34
weeks gestation).
Some studies were retrospective, but since they were using con-
temporaneous notes, there is a limit to the effect this could have had.
The intervention, the KP EOS calculator, was the same across the
studies. The outcome was well deﬁned and consistent: was the EOS
score greater or less than 3/1000 births.
Compared to current guidance, the calculator failed to recom-
mend treatment in at least 14/75 babies with EOS (and possibly up to
22 babies) who would have been treated using NICE guidelines. This
is in addition to any babies who will inevitably be missed by the NICE
guidelines. The baby with E.coli, for example, in Stipelman 2019 [20]
had an isolated temperature of>38 °C, which would not trigger treat-
ment based on NICE guidelines, however the clinician decided to
commence antibiotics. The EOS score was <3/1000 and so the calcu-
lator would also not have recommended treatment and would have
missed this case.
The impressive reduction in the use of antibiotics which can be
achieved with the calculator can be seen in Table 3, e.g. from 5% to
2.6% in Kuzniewicz et al. [3], or in babies exposed to chorioamnionitis
one paper demonstrated a potential reduction from 99.7% to 2.5%
[17]. However, given the low sensitivity we have demonstrated, we
RE Model
0 0.2 0.4 0.6 0.8 1
Proportion of missed cases
Joshi 2019
Sharma 2019
Carola 2018
Money 2017
Shakib 2015
Stipelman 2019
Arora 2019
Goel 2019
Strunk 2018
Dhudasia 2018
Kuzniewicz − calculator period
Kuzniewicz − learning period
Kuzniewicz − baseline period
0.75 [0.11, 0.99]
0.25 [0.01, 0.89]
0.20 [0.03, 0.69]
0.75 [0.11, 0.99]
0.25 [0.01, 0.89]
0.67 [0.15, 0.96]
0.25 [0.01, 0.89]
0.08 [0.01, 0.62]
0.17 [0.01, 0.81]
0.25 [0.03, 0.76]
0.17 [0.04, 0.48]
0.13 [0.03, 0.41]
0.17 [0.06, 0.37]
0.19 [0.11, 0.29]
Proportion [95% CI]Study
Fig. 2. Proportion of cases missed by the calculator (additional to any cases missed by NICE), all studies best case scenario.
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believe that the risks of introducing this tool do not outweigh the
beneﬁts. Potential delays in antibiotic administration by using the
calculator have been highlighted previously, in a letter to JAMA pedi-
atrics by Rajbhandari et al. [21]. This was rebutted by Kuzniewicz and
colleagues, explaining that any potential delays in treatment are far
outweighed by the dramatic reduction in antibiotics which they have
achieved [22].
Difference in microbiology and in healthcare practices between
the UK and the USA are signiﬁcant in this context. In the UK for exam-
ple, GBS screening is not routine, observation nurseries (as described
by Money et al.) are not common, prolonged stays on post-natal
wards for babies not receiving antibiotics are unusual, and paediatri-
cians are unlikely to ever encounter the majority of babies, as most
care is delivered by midwives. When the EOS calculation is low risk,
the calculator recommends “routine vitals”. However, the majority of
UK babies would not have routine observations carried out at all,
unless there was clinical concern.
Kuzniewicz et al., point out that “if adopting out approach, individ-
ual centers must assess local care structures” [3]. If the calculator were
to be adopted in the UK, current postnatal care would have to be
adapted. For example, if a baby who would have qualiﬁed for obser-
vations due to one risk factor as per NICE has a low EOS risk score,
would they be allowed to go home after 6 h? Clearly, robust local pol-
icies would need to be drawn up on exactly how the calculator were
to be used.
It is striking that in all the available evidence there were only 75
cases of EOS. Collins et al. demonstrate that effective evaluation of a pre-
diction model would require at least 100 (and possibly 200) external
cases, to validate the model [23]. We would suggest this be carried out
retrospectively by accumulating a large series of cases of babies evalu-
ated for sepsis (whilst continuing to use NICE guidelines) rather than
rolling out the calculator and potentially missing further cases of EOS.
We have not carried out a corresponding meta-analysis to deter-
mine the number of misses that NICE guidelines might have com-
pared to the calculator. Given the broad recommendations for
antibiotic use in the NICE guidelines, this was felt unlikely to be bene-
ﬁcial. This study evaluates the sensitivity of the calculator compared
to NICE guidelines. We have not made any assessment of its speciﬁc-
ity, or its safety when implemented with a whole-nursery system of
newborn care. This study does not make a comprehensive assess-
ment of the overall performance of the calculator, rather we have
assessed its immediate ability to accurately detect babies who go on
to have positive blood cultures.
Whether the beneﬁts of reducing antibiotics use outweigh the
occasional ‘miss’ or delay is hard to quantify, since it is difﬁcult to
estimate the effects of widespread (over)use of antibiotics to individ-
uals and populations. This meta-analysis has demonstrated that a
large proportion of true cases of EOS are ‘missed’ by the calculator, in
addition to those which would be missed by NICE guidelines. The
probability of missing additional cases compared to the NICE
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Fig. 3. Proportion of cases missed by the calculator (additional to any cases missed by NICE), all studiesworst case scenario.
8 K.J. Pettinger et al. / EClinicalMedicine 19 (2020) 100227
RE Model
0 0.2 0.4 0.6 0.8 1
Proportion of missed cases
Stipelman 2019
Arora 2019
Goel 2019
Strunk 2018
Dhudasia 2018
Kuzniewicz − calculator period
Kuzniewicz − learning period
Kuzniewicz − baseline period
0.67 [0.15, 0.96]
0.25 [0.01, 0.89]
0.08 [0.01, 0.62]
0.17 [0.01, 0.81]
0.25 [0.03, 0.76]
0.17 [0.04, 0.48]
0.13 [0.03, 0.41]
0.17 [0.06, 0.37]
0.17 [0.09, 0.28]
Proportion [95% CI]Study
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Fig. 5. Proportion of cases missed by the calculator (additional to any cases missed by NICE), whole cohort studiesworst case scenario.
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Fig. 7. Proportion of cases missed by the calculator (additional to any cases missed by NICE), chorioamnionitis exposed babiesworst case scenario.
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guidelines is signiﬁcantly higher amongst babies exposed to cho-
rioamnionitis.
Given these concerns, further analyses of known cases of EOS is
required to determine what proportion would be initially missed or
result in delayed treatment. No method for predicting EOS is perfect,
and there is no substitute for clinical monitoring, since there will
almost inevitably be some babies without risk factors for infection
who nevertheless go onto to become septic. Effective evaluation will
need approximately 100 cases of EOS to have occurred, a threshold
not yet reached in the available literature.
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